A new study by Johns Hopkins Medicine researchers compared psychedelic experiences with near-death experiences that were not drug-related, finding notable similarities in people’s attitudes toward death.
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.
A new study conducted by Columbia University Mailman School of Public Health and Columbia University Irving Medical Center estimates that over 5.5 million people in the US used hallucinogens...
Optimi Health has received approval from Health Canada to manufacture and distribute psychedelic medicines.
Awakn Life Sciences is expanding its commercial operations into the US through its first licensing partnership with Revitalist Lifestyle and Wellness – one of the largest...
The 2022 International Forum on Consciousness returns with its 2022 topic “As Above, So Below”, and will feature a diverse group of thought leaders to explore...
Optimi Health has launched Blue Serenity – Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.
The Microdosing Collective has stated it is committed to a world where sub-perceptible microdosing of psychedelics is legal, accessible and safe.
COMPASS Pathways has launched its multi-centre, doubleblind randomised controlled Phase 2 clinical trial investigating the efficacy of its proprietary formulation of synthetic psilocybin, COMP360, in people...
The UNC School of Medicine has found that variants in one serotonin receptor in neurons could be why some patients fare much better after psychedelic therapy...